Open AccessFormulation and evaluation of Lamivudinefloating tablets usingCarbopol & Eudragit S 100
Author(s) -
C Kalaiselvi,
C Jothimanivannan,
M Gomathi,
Praveen KumarM
Publication year - 2022
Publication title -
world journal of pharmaceutical sciences
Language(s) - English
Resource type - Journals
eISSN - 2321-3310
pISSN - 2321-3086
DOI - 10.54037/wjps.2022.100304
Subject(s) - bioavailability , stomach , drug , absorption (acoustics) , dosage form , pharmacology , immediate release , controlled release , chemistry , medicine , materials science , composite material
Lamivudinecomes underclass II drugs according to BCS classification. It is poorly water-soluble drug. It has maximum solubility in pH 1.2 and therefore it will be beneficial to retain the drug in stomach for longer period of time for better absorption. Hence, it was found necessary to develop a gastric retentive dosage form containing Lamivudinein order to increase the gastric residence time to enhance its absorption and they’re by its oral bioavailability. Also, the slow release of the drug in stomach may avoid the stomach pain associated with immediate release of the drug. The ultimate aim was to design, develop and optimize the floating tablets containing Lamivudinein order to increase its gastric retention time for enhancing absorption in stomach as well as to produce a controlled release of the drug for a longer time using polymers such as Carbopol, and EudragitS100.